|
1
|
Pal SK, Ghate SR, Li N, Swallow E, Peeples
M, Zichlin ML, Perez JR, Agarwal N and Vogelzang NJ: Real-world
survival outcomes and prognostic factors among patients receiving
first targeted therapy for advanced renal cell carcinoma: A
SEER-medicare database analysis. Clin Genitourin Cancer.
15:e573–e582. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Issa JP: CpG island methylator phenotype
in cancer. Nat Rev Cancer. 4:988–993. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lasseigne BN and Brooks JD: The role of
DNA methylation in renal cell carcinoma. Mol Diagn Ther.
22:431–442. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mendoza-Pérez J, Gu J, Herrera LA, Tannir
NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG and Wu X:
Genomic DNA hypomethylation and risk of renal cell carcinoma: A
case-control study. Clin Cancer Res. 22:2074–2082. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herman JG, Latif F, Weng Y, Lerman MI,
Zbar B, Liu S, Samid D, Duan DS, Gnarra JR and Linehan WM:
Silencing of the VHL tumor-suppressor gene by DNA methylation in
renal carcinoma. Proc Natl Acad Sci USA. 91:9700–9704. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ricketts CJ, De Cubas AA, Fan H, Smith CC,
Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, et al:
The Cancer genome atlas comprehensive molecular characterization of
renal cell carcinoma. Cell Rep. 23:313–326 e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Battagli C, Uzzo RG, Dulaimi E, Ibanez de
Caceres I, Krassenstein R, Al-Saleem T, Greenberg RE and Cairns P:
Promoter hypermethylation of tumor suppressor genes in urine from
kidney cancer patients. Cancer Res. 63:8695–8699. 2003.PubMed/NCBI
|
|
10
|
Slater AA, Alokail M, Gentle D, Yao M,
Kovacs G, Maher ER and Latif F: DNA methylation profiling
distinguishes histological subtypes of renal cell carcinoma.
Epigenetics. 8:252–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Malouf GG, Su X, Zhang J, Creighton CJ, Ho
TH, Lu Y, Raynal NJ, Karam JA, Tamboli P, Allanick F, et al: DNA
methylation signature reveals cell ontogeny of renal cell
carcinomas. Clin Cancer Res. 22:6236–6246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morris MR, Ricketts CJ, Gentle D, McRonald
F, Carli N, Khalili H, Brown M, Kishida T, Yao M, Banks RE, et al:
Genome-wide methylation analysis identifies epigenetically
inactivated candidate tumour suppressor genes in renal cell
carcinoma. Oncogene. 30:1390–1401. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Klatte T, Rossi SH and Stewart GD:
Prognostic factors and prognostic models for renal cell carcinoma:
A literature review. World J Urol. 36:1943–1952. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Choueiri TK, Fay AP, Gagnon R, Lin Y,
Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL,
Carpenter C, et al: The role of aberrant VHL/HIF pathway elements
in predicting clinical outcome to pazopanib therapy in patients
with metastatic clear-cell renal cell carcinoma. Clin Cancer Res.
19:5218–5226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stewart GD, O'Mahony FC, Laird A, Eory L,
Lubbock AL, Mackay A, Nanda J, O'Donnell M, Mullen P, McNeill SA,
et al: Sunitinib treatment exacerbates intratumoral heterogeneity
in metastatic renal cancer. Clin Cancer Res. 21:4212–4223. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Peters I, Dubrowinskaja N, Abbas M, Seidel
C, Kogosov M, Scherer R, Gebauer K, Merseburger AS, Kuczyk MA,
Grünwald V and Serth J: DNA methylation biomarkers predict
progression-free and overall survival of metastatic renal cell
cancer (mRCC) treated with antiangiogenic therapies. PLoS One.
9:e914402014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dubrowinskaja N, Gebauer K, Peters I,
Hennenlotter J, Abbas M, Scherer R, Tezval H, Merseburger AS,
Stenzl A, Grünwald V, et al: Neurofilament Heavy polypeptide CpG
island methylation associates with prognosis of renal cell
carcinoma and prediction of antivascular endothelial growth factor
therapy response. Cancer Med. 3:300–309. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu J, Jin L, Li Y, He T, Liu J, Shi B,
Yang S, Gui Y, Mao X, Lai Y and Ni L: Multilocular cystic renal
cell carcinoma: A case report and review of the literature. Mol
Clin Oncol. 8:326–329. 2018.PubMed/NCBI
|
|
19
|
Kubiak-Wlekly A and Niemir ZI:
Neprilysin-structure of the gene and protein product and the
localization of expression. Pol Merkur Lekarski. 27:48–50. 2009.(In
Polish). PubMed/NCBI
|
|
20
|
van Vlodrop IJ, Niessen HE, Derks S,
Baldewijns MM, van Criekinge W, Herman JG and van Engeland M:
Analysis of promoter CpG island hypermethylation in cancer:
Location, location, location! Clin Cancer Res. 17:4225–4231. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morris MR, Ricketts C, Gentle D,
Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F and
Maher ER: Identification of candidate tumour suppressor genes
frequently methylated in renal cell carcinoma. Oncogene.
29:2104–2117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sreekumar A, Poisson LM, Rajendiran TM,
Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, et al:
Metabolomic profiles delineate potential role for sarcosine in
prostate cancer progression. Nature. 457:910–914. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martínez-Chantar ML, Vázquez-Chantada M,
Ariz U, Martínez N, Varela M, Luka Z, Capdevila A, Rodríguez J,
Aransay AM, Matthiesen R, et al: Loss of the glycine
N-methyltransferase gene leads to steatosis and hepatocellular
carcinoma in mice. Hepatology. 47:1191–1199. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen YM, Shiu JY, Tzeng SJ, Shih LS, Chen
YJ, Lui WY and Chen PH: Characterization of
glycine-N-methyltransferase-gene expression in human hepatocellular
carcinoma. Int J Cancer. 75:787–793. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lim SO, Park SJ, Kim W, Park SG, Kim HJ,
Kim YI, Sohn TS, Noh JH and Jung G: Proteome analysis of
hepatocellular carcinoma. Biochem Biophys Res Commun.
291:1031–1037. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Waalkes S, Atschekzei F, Kramer MW,
Hennenlotter J, Vetter G, Becker JU, Stenzl A, Merseburger AS,
Schrader AJ, Kuczyk MA and Serth J: Fibronectin 1 mRNA expression
correlates with advanced disease in renal cancer. BMC Cancer.
10:5032010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gebauer K, Peters I, Dubrowinskaja N,
Hennenlotter J, Abbas M, Scherer R, Tezval H, Merseburger AS,
Stenzl A, Kuczyk MA and Serth J: Hsa-mir-124-3 CpG island
methylation is associated with advanced tumours and disease
recurrence of patients with clear cell renal cell carcinoma. Br J
Cancer. 108:131–138. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eschenbrenner M and Jorns MS: Cloning and
mapping of the cDNA for human sarcosine dehydrogenase, a
flavoenzyme defective in patients with sarcosinemia. Genomics.
59:300–308. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Colella S, Shen L, Baggerly KA, Issa JP
and Krahe R: Sensitive and quantitative universal Pyrosequencing
methylation analysis of CpG sites. Biotechniques. 35:146–150. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tezval H, Dubrowinskaja N, Peters I, Reese
C, Serth K, Atschekzei F, Hennenlotter J, Stenzl A, Kuczyk MA and
Serth J: Tumor specific epigenetic silencing of corticotropin
releasing hormone -binding protein in renal cell carcinoma:
Association of hypermethylation and metastasis. PLoS One.
11:e01638732016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Heger Z, Merlos Rodrigo MA, Michalek P,
Polanska H, Masarik M, Vit V, Plevova M, Pacik D, Eckschlager T,
Stiborova M and Adam V: Sarcosine up-regulates expression of genes
involved in cell cycle progression of metastatic models of prostate
cancer. PLoS One. 11:e01658302016. View Article : Google Scholar : PubMed/NCBI
|
